Holen Sie sich die Stockscreener-App
11.79
3.04%
-0.37
Handel nachbörslich:
11.70
-0.09
-0.76%
Schlusskurs vom Vortag:
$12.16
Offen:
$12.15
24-Stunden-Volumen:
9.42M
Relative Volume:
4.54
Marktkapitalisierung:
$1.59B
Einnahmen:
$177.28M
Nettoeinkommen (Verlust:
$-195.24M
KGV:
-8.7985
EPS:
-1.34
Netto-Cashflow:
$-114.54M
1W Leistung:
+13.58%
1M Leistung:
+28.99%
6M Leistung:
+87.44%
1J Leistung:
+240.75%
1-Tages-Spanne:
$11.56
$12.30
1-Wochen-Bereich:
$10.20
$12.43
52-Wochen-Spanne:
$3.30
$12.43
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Vergleichen Sie ADPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
11.79 | 1.59B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Cathie Wood’s ARK buys BWX stock, sells Adaptive Biotech - Investing.com
Adaptive Biotechnologies (ADPT) Initiates Coverage with Buy Rating | ADPT Stock News - GuruFocus
Adaptive Biotechnologies (ADPT) Sees Positive Growth Prospects | - GuruFocus
Assessing Adaptive Biotechnologies: Insights From 5 Financial Analysts - Nasdaq
Adaptive Biotechnologies (ADPT) Receives New Buy Rating and Pric - GuruFocus
Adaptive Biotechnologies reports annual meeting outcomes By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies reports annual meeting outcomes - Investing.com
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Bought by California State Teachers Retirement System - Defense World
Adaptive Biotechnologies at Goldman Sachs Conference: Strong Q1 Performance and Strategic Growth - Investing.com
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
118,593 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Squarepoint Ops LLC Raises Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Nasdaq Today Adaptive Biotechnologies’ Role in Innovation Kalkine - Kalkine Media
ADPT stock soars to 52-week high, hits $10.28 amid surge - Investing.com India
Two Sigma Advisers LP Has $309,000 Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Two Sigma Investments LP Has $1.10 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Bank of America Corp DE - Defense World
Cathie Wood’s ARK buys Guardant Health, sells Adaptive Biotechnologies stock - Investing.com Nigeria
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at Key Conferences | ADPT Stock News - GuruFocus
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers - The Manila Times
Adaptive Biotechnologies’ MRD test featured in cancer studies - Investing.com
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
BNP Paribas Financial Markets Reduces Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Cathie Wood’s ARK buys CRISPR, sells Adaptive Biotech stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys CRISPR, sells Adaptive Biotech stock - Investing.com
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Ameriprise Financial Inc. Has $4.42 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Janus Henderson Group PLC Buys Shares of 46,900 Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Catherine Wood Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus
Northern Trust Corp Acquires 130,449 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Jane Street Group LLC Sells 97,690 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Holdings Lowered by Price T Rowe Associates Inc. MD - Defense World
Does Adaptive Biotechnologies Corp (NASDAQ: ADPT) Still Look Hot This Week? - Stocksregister
16,457 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by First Trust Advisors LP - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect? - Yahoo Finance
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? - Yahoo Finance
FDA posts regulation for 2018 test for hematological malignancies - BioWorld MedTech
Brokerages Set Adaptive Biotechnologies Co. (NASDAQ:ADPT) Price Target at $9.50 - Defense World
Trading Day Review: Adaptive Biotechnologies Corp (ADPT) Loses Momentum, Closing at 8.81 - DWinneX
MetLife Investment Management LLC Acquires 3,650 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies (ADPT) Price Target Raised by Piper San - GuruFocus
Adaptive Biotechnologies (ADPT) Price Target Raised by Piper Sandler | ADPT Stock News - GuruFocus
Adaptive Biotechnologies Reaches Analyst Target Price - Nasdaq
ADPT Price Target Increased to $13 by Piper Sandler | ADPT Stock News - GuruFocus
Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading Volume Following Analyst Upgrade - Defense World
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Adaptive Biotechnologies Corp-Aktie (ADPT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROBINS HARLAN S | Chief Scientific Officer |
May 01 '25 |
Option Exercise |
6.32 |
68,412 |
432,364 |
1,347,936 |
| ROBINS HARLAN S | Chief Scientific Officer |
May 01 '25 |
Sale |
7.35 |
68,412 |
502,828 |
1,279,524 |
1.11%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):